Bryan Johnson· Author
A @NatureAging study found pTau217 levels in healthy people predicted future cognitive decline as accurately as brain scans.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
A @NatureAging study found pTau217 levels in healthy people predicted future cognitive decline as accurately as brain scans.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Higher pTau217 levels = faster cognitive decline.
pTau217 and A𝛃42 are recent FDA-approved biomarkers for Alzheimer's detection in symptomatic patients.
+ Top 25% pTau217 = 57% increased risk
Cognitively unimpaired individuals with pTau217 levels in the highest 25% showed a 57% elevated risk of future cognitive decline.
Serum pTAU217 is a marker for Alzheimer's disease.
Cognitively unimpaired individuals in the highest 25% of pTau217 levels demonstrated a 57% elevated risk of future cognitive decline.
Elevated concentrations of p-TAU217 can also be detected in the blood, higher concentrations predict faster disease progression.
The research proposes that p-TAU217 can serve as an initial screening tool in healthy individuals.